Improving Adherence and Clinical Outcome in Cystic Fibrosis (CF) Patients
|Cystic Fibrosis||Behavioral: Frequent Scheduled CF clinic visits Behavioral: frequent telephone calls to patients pre and post visits to the clinic|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Improving Adherence and Clinical Outcomes of Cystic Fibrosis Patients Through a Collaborative Active Intervention Program of a Multidisciplinary Team|
- To determine whether a collaborative intervention program of a multi disciplinary team improves clinical outcomes such as: number of hospital admissions, number of IV ABx courses, and change in %FEV1, BMI. [ Time Frame: 6 months, 12 months ]
- To determine whether a collaborative intervention program of a multi disciplinary team improves adherence to routinely prescribed CF medications: Tobi, Pulmozyme, Colistine , HS, Creon and AquADEKs multivitamins. [ Time Frame: 6 months, 12 months ]
- To determine whether a collaborative intervention program of a multi-disciplinary team improves health related quality of life. [ Time Frame: 6 months, 12 months ]
- To inspect whether improved adherence to medications during intensive care for 1 year in CF will reduce cytokines and inflammatory markers [ Time Frame: 6 months, 12 months ]
|Study Start Date:||December 2009|
|Study Completion Date:||June 2011|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
|Active Comparator: frequent clinic visits||
Behavioral: Frequent Scheduled CF clinic visits
Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacistBehavioral: frequent telephone calls to patients pre and post visits to the clinic
Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
Cystic fibrosis is a life-threatening hereditary multi-system disease predominantly affecting the pancreas and lungs. Advances in treatment have led to significant improvements in prognosis though this depends crucially upon adherence to treatment.
It has been demonstrated in chronic conditions that improving medication adherence can improve clinical outcome, though it can be a difficult and complex task.
This is the first trial assessing the impact of a collaborative active intervention program of a multi disciplinary team in improving adherence to specific chronic medications and improving clinical outcomes in CF patients.
The trial will be divided into two parts:
First Part The first part of the trial will be a retrospective one in which data will be collected at baseline, from eligible patient files and patients' pharmacy records receiving standard care for the past 12 months.
Second Part The second part of the trial will be an active interventional prospective one and will be conducted for 12 months. The active intervention will be composed of series of visits of patients attending the clinic every 2 months (or sooner, if needed) in which a specialized CF team member will follow on the progress of the patient in his field of expertise. Furthermore, frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated team member such as the CF nurse or the CF clinical pharmacist.
On identifying problems concerning medication adherence (such as: difficulties receiving medications from the sick fund, unwillingness to do inhaled medications because of allegedly side effects, difficulties in swallowing pills, etc.) solutions will be suggested by the CF team members and will be examined accordingly on the following visits.
Adherence to specific chronic medications will be determined by a short self reported questionnaire, a structured interview with the clinical pharmacist and prescriptions refill history obtained from pharmacy records in every visit to the clinical pharmacist.
Outcomes will be measured from patient's hospital records at baseline, 6 months and 12 months from the starting point. Measured clinical outcomes will be: PFTs, number of hospital admissions, number of exacerbations, number of IV courses, time between each exacerbation, inflammatory markers, BMI, HRQoL.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01025258
|Pediatric pulmonary unit, The Edmod and Lili Safra children's Hospital, Sheba Medical Center|
|Principal Investigator:||Ori Efrati, MD||Sheba Medical Center|
|Study Director:||Vardit M Kalamaro, BPharm, MSc||The Israeli Cystic Fibrosis Foundation|
|Study Chair:||Ran Nissan, Pharm D Student||Hebrew University of Jerusalem|